Novartis holds steady in Swiss large caps, Tuesday focus on analyst views and SMI peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 17:55.

Novartis (CH0012005267) starts Tuesday as one of the heavyweight constituents of the Swiss Market Index on SIX Swiss Exchange. The stock remains a core Swiss large cap in the pharmaceutical segment, with investors watching updated consensus data and peer performance in SMI healthcare names such as Roche and Lonza.

What consensus data show today

Consensus overviews collected by MarketScreener and Swiss broker platforms still characterize Novartis as a widely covered blue chip, with more than 20 active analyst ratings from international houses including UBS, JPMorgan and Goldman Sachs. Most of these ratings sit in the Buy or Outperform range, while a minority of houses recommend Hold, reflecting a cautiously constructive stance on the stock. The average twelve-month price target in recent summaries remains moderately above the current share price in Swiss francs, indicating expectations for mid-single-digit upside rather than aggressive growth. Retail investors thus see a picture of broad but measured support from the sell-side community for Novartis as a defensive healthcare holding.

How Novartis compares to SMI peers

Within the SMI, Novartis is one of the three major pharmaceutical names alongside Roche and Alcon, and it features prominently in sector comparisons on platforms such as finanzen.ch and finanzen100. In these peer tables the stock is typically benchmarked by dividend yield, valuation multiples and year-to-date performance, with Novartis showing a mix of moderate growth and solid income characteristics. In recent weeks, Swiss market commentaries have described the broader SLI and SMI indices as trading somewhat firmer, with technology names grabbing more of the momentum while pharmaceuticals like Novartis offer stability. For private investors, that positioning as a stabilizing anchor in a mixed sector environment is part of the appeal.

The products behind the stock

Novartis generates revenue primarily from innovative prescription medicines across therapeutic areas such as oncology, immunology, neuroscience and cardiometabolic diseases. Recent pipeline communication has highlighted assets like Rhapsido for chronic inducible urticaria, where Phase III data met primary endpoints and pointed towards potential first-in-class targeted treatment options. In addition, legacy blockbuster franchises in cardiovascular and ophthalmology continue to contribute meaningful cash flows, supporting both research spending and shareholder returns.

Where Novartis shares trade today

Novartis shares (CH0012005267) last traded on SIX Swiss Exchange at 121.96 Swiss francs as of 2026-06-23, 10:03, according to finanzen.ch. This places the stock in the middle of its recent trading range, consistent with its role as a defensive large cap in the SMI.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to purchase any financial instrument. All data are based on sources cited in the text and may change over time.